Get the Stockscreener App
0.571
11.36%
-0.0732
After Hours:
.57
-0.001
-0.18%
Transcode Therapeutics Inc stock is traded at $0.571, with a volume of 907.81K.
It is down -11.36% in the last 24 hours and up +116.78% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$0.6442
Open:
$0.63
24h Volume:
907.81K
Relative Volume:
0.54
Market Cap:
$9.84M
Revenue:
-
Net Income/Loss:
$-19.59M
P/E Ratio:
-0.0235
EPS:
-24.29
Net Cash Flow:
$-16.49M
1W Performance:
+85.93%
1M Performance:
+116.78%
6M Performance:
-16.40%
1Y Performance:
-97.16%
1-Day Range:
$0.5601
$0.6348
1-Week Range:
$0.32
$0.73
52-Week Range:
$0.216
$21.20
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Transcode Therapeutics faces potential Nasdaq delisting - Investing.com
TransCode Therapeutics Inc (RNAZ): Worth A Small Bite At $0.62 - Stocks Register
TransCode Therapeutics Begins Dosing Patients in Phase 1 Trial for Metastatic Cancer Therapy - Proactive Investors USA
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.70% - MSN
TransCode Therapeutics Inc (RNAZ) expanding its growth trajectory ahead - SETE News
Gaining Ground: TransCode Therapeutics Inc (RNAZ) Closes Higher at 0.42, Up 35.75 - The Dwinnex
TransCode Therapeutics Inc (RNAZ) presents a great opportunity, but the stock is slightly undervalued - US Post News
Ratio Review: Analyzing TransCode Therapeutics Inc (RNAZ)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Taking the lead: TransCode Therapeutics Inc (RNAZ) - SETE News
Recent Insider Activity Could Benefit Ocean Power Technologies (OPTT) - Knox Daily
W.R. Berkley Corp. [WRB] Investment Appeal on the Rise - Knox Daily
TransCode begins Phase 1 trial of metastatic cancer treatment By Investing.com - Investing.com Canada
RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
RNAZ’s price-to-sales ratio: A comparative analysis with its peers - US Post News
TransCode begins Phase 1 trial of metastatic cancer treatment - Investing.com
TransCode begins Phase 1 trial of metastatic cancer treatment - Investing.com India
TransCode begins Phase 1 trial of metastatic cancer treatment By Investing.com - Investing.com UK
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - StockTitan
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Australia
Transcode Therapeutics announces publication of study on TTX-MC138 - TipRanks
TransCode reports progress in metastatic breast cancer treatment - Investing.com
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com Canada
Upward Trajectory: TransCode Therapeutics Inc (RNAZ) Posts a Slidee, Closing at 0.26 - The Dwinnex
TransCode reports progress in metastatic breast cancer treatment By Investing.com - Investing.com UK
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing - The Bakersfield Californian
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer - StockTitan
Do investors need to be concerned about TransCode Therapeutics Inc (RNAZ)? - US Post News
TransCode Therapeutics (NASDAQ:RNAZ) Rating Reiterated by HC Wainwright - Defense World
TransCode shares hold price target as analyst reiterates Buy rating - Investing.com
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Transcode Therapeutics awarded $2M NIH grant to support TTX-MC138 - TipRanks
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate - StockTitan
Examining TransCode Therapeutics Inc (RNAZ) more closely is necessary - US Post News
Eyenovia Inc’s latest rating changes from various analysts - Knox Daily
Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer - MSN
TransCode Therapeutics (NASDAQ:RNAZ) Stock Quotes, Forecast and News Summary - Benzinga
TransCode Therapeutics faces Nasdaq delisting over equity, price By Investing.com - Investing.com Australia
Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer - News-Medical.Net
Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer - Head Topics
miR-10b inhibition: A strategy for treating metastatic breast cancer - Medical Xpress
TransCode Therapeutics faces Nasdaq delisting over equity, price By Investing.com - Investing.com Canada
TransCode Therapeutics faces Nasdaq delisting over equity, price - Investing.com
miR-10b Inhibition: A strategy for treating metastatic breast cancer - EurekAlert
Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock Quotes, Forecast and News Summary - Benzinga
TransCode Therapeutics Inc (RNAZ) can make a big difference with a little luck - SETE News
Analytical Lens: Exploring TransCode Therapeutics Inc (RNAZ)’s Financial Story Through Ratios - The Dwinnex
Associated Banc-Corp (NYSE:ASB) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Transcode Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com Australia
TransCode Therapeutics (NASDAQ:RNAZ) Stock Rating Reaffirmed by HC Wainwright - Defense World
SG Americas Securities LLC Acquires New Holdings in Spirit AeroSystems Holdings, Inc. (NYSE:SPR) - Defense World
Transcode Therapeutics faces Nasdaq delisting over bid price - Investing.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):